Invest in Health in the University's West End Development
The University is committed to developing partnerships to deliver positive impacts through innovation, research, education and community engagement within the West End development.
See below for the contacts for different partnerships arrangements.
Some of our partnering projects include:
- Research partnerships
- Contract research
- Professional consulting
- Expert witness
- Access intellectual property
- Licensing curriculum
- Scholarships and sponsorships within industry
- Supporting education (scholarships & prizes)
- Supporting research
- Sponsoring equipment/facilities
Benefits to partnering with the University of Adelaide
- Own a piece of Adelaide's history
- Create a legacy for future generations
- Support work ready, highly skilled graduates
- Enable life-changing research and development
Successful partnerships in the Faculty of Health and Medical Sciences
- Product development and commercialisation - EmbryoGen
A collaborative partnership between the University, ARI, and Origio a/s, a world leader in assisted reproductive technology solutions, has resulted in the development of EmbryoGen®, a novel treatment option for women undergoing IVF who have had one or more previous miscarriages.
The partnership began in 2004, when ARI approached Origio a/s with an innovative fertility culture medium for growing embryos.
The culture medium contains a signalling molecule called GM-CSF found naturally in the mother’s tissues that protects the embryo from stress, making it stronger and more robust in the early implantation period, meaning fewer miscarriages for IVF patients.
The product was the culmination of more than two decades' work for Professor Sarah Robertson, a reproductive biologist, NHMRC Principal Research Fellow and member of the University's Robinson Institute.
Attracted by the science, and convinced of the commercial applicability of the technology, Origio a/s licensed the IP for the culture medium, and undertook the world’s largest fertility media study to verify Professor Robertson’s findings, and develop the world’s first natural growth factor medium with proven effect.
In a major commercial breakthrough, the US Food and Drug Administration (FDA) have now approved EmbryoGen® to be marketed in the US, clearing the way for its use in one of the world’s biggest markets.
The US decision follows earlier decisions by authorities in other major markets such as Europe, China and the Middle East to allow the use of the medium.
Now available in over 40 countries, EmbryoGen® is making a difference to the lives of real people. Origio a/s has received letters from grateful embryologists all around Europe, who have been able to help people as a result of this technology. Source: http://www.adelaideresearch.com.au/projects/embryogen/
- Translational science - Wolters Kluwer Health
The University entered an exclusive partnership with Wolters Kluwer Health, one of the world's leading providers of health products and services to provide exclusive online access of its resources and information.
"The Joanna Briggs Institute [now the School of Translational Science] is the acknowledged leader in translational research in clinical care and therapeutics, including the creation of systematic reviews, evidence summaries and the tools needed to embed these into health processes. We are delighted to be partnering with them," the President and CEO of Walters Kluwer Health Medical Research, Karen Abramson said.
- Government partnership - Adelaide Health Technology Assessment (AHTA)
Adelaide Health Technology Assessment (AHTA) has several contracts with the Australian Government Department of Health and Ageing to perform health technology assessments on behalf of both Medical Services Advisory Committee (MSAC) and Pharmaceutical Benefits Advisory Committee (PBAC). In this role, they collate, appraise and synthesise existing clinical evidence (research) on medical technologies and health interventions, develop economic models, and provide an evaluation of their safety, clinical and cost effectiveness compared with other treatments, as well as their likely impact on the health system.
- Early stage medical research - Mesoblast
The University has assigned stem cell technology to Mesoblast, an Australian regenerative medicine giant, in a deal which would lead to a treatment for stroke sufferers. The product is yet to go through pre-clinical and clinical trials prior to commercialisation and the up-front assignment fee is being reinvested into further stroke research.
For all alumni, donation, foundation, sponsorships fundraising and events enquiries
Ms Josie Gray | Research Fundraising Officer
Office of Research Development and Research Education, Faculty of Health and Medical Sciences
T: +61 8 8313 9939 | E: email@example.com
To recruit quality graduates